Robert B Chao, MD doctorRBC
3 years 10 months ago
Bimekizumab (IL-17A and IL-17F inhibitor) use in non-radiographic AxSpA resulted in rapid improvement of ASAS40 along with reduction in SPARCC MRI SI joint inflammation
#Abs0544 @RheumNow #ACR22 https://t.co/pOCg0idGsR
sheila RHEUMarampa
3 years 10 months ago
2022 ACR guide for #vaccinations in RMD pts:
💉Influenza:⬆️dose or adjuvant (CR) >=65 & >18<65 on immunosuppressives
💉Pneumococcal: SR for <65 yrs, on immunosuppressives
💉Rec VZV: SR for >18y on immunosupressives
💉HPV: CR for >26y & <45y on meds & no prev vax
#ACR22 @rheumnow https://t.co/2DlIqNUBct
David Liew drdavidliew
3 years 10 months ago
What do you look for on temporal artery examination in GCA assessment?
tenderness: minimally useful
reduced/absent pulse or thickening: quite good if there, nearly as good as halo
Good examination is powerful, if you're doing it right!
ABST0483 Salvarani group #ACR22 @RheumNow https://t.co/B3qvSW68at
Dr. Rachel Tate uptoTate
3 years 10 months ago
Abs 0406 demonstrates stronger relationship between disease activity (using BASFI and BASDAI) and quality of life in men w/ axSpA than women. IMO, it also demonstrates need for better assessment tools for women! #ACR22 @RheumNow https://t.co/B44ZixyeAJ https://t.co/lMzpsGcsFM
Rheumatoid arthritis is known to be associated with a higher risk of infections. In abstract 0535, Porter and colleagues have assessed infection rates in the pre-RA and early RA phases as defined by antibiotics prescription and hospital admissions with an infection main diagnostic code in the UK National database.
Dr. Rachel Tate uptoTate
3 years 10 months ago
Abs0399 ASAS recs for requesting/reporting imaging in suspected AxSpA pts key takeaway: communication!
Rheum provides pertinent hx (trauma, childbirth, pain location, duration, etc), DDx
Rads summarize hx & give pertinent +/- exam findings
#ACR22 @RheumNow https://t.co/Ucr8B5xfGA https://t.co/F6g15dQhj1
Robert B Chao, MD doctorRBC
3 years 10 months ago
2022 ASAS-EULAR Recommendations of AxSpA management
1) NSAIDs still first line
2) Analgesics/opioids contraindicated
3) TNFi, IL-17i first line bDMARDs, followed by JAKinibs
4) Tapering but not discontinuation of bDMARDs in sustained remission
Abs#0542 @RheumNow #ACR22 https://t.co/ffaN2fMc3v
Dr. John Cush RheumNow
3 years 10 months ago
Saturday: ACR 2022 Daily Recap https://t.co/3WGcxsEtOj
Dr. John Cush RheumNow
3 years 10 months ago
Emerging and exciting treatments in RA: #ACR22 preview
https://t.co/5JtblF9MxE https://t.co/oYSiLguLkJ
Aurelie Najm AurelieRheumo
3 years 10 months ago
Are DNA methylation marks the new seronegative RA biomarkers?
Riskedal et al. propose a new model based on whole-blood DNAm profiles
Sens 90%, Spe 88%, Accuracy 89% for classification of RA
Accuracy RA Sero+ 100%, RA Sero- 75%
https://t.co/3occAQPZ1u Abs#0531 #ACR22 @Rheumnow https://t.co/QXhMxyWC8g
Richard Conway RichardPAConway
3 years 10 months ago
Terrier @TerrierBen . Pooled analysis of MAINRITSAN trials. For major relapse at 84 months RTX>AZA HR 2.5. RTX fixed-dose>tailored HR 3. RTX 18 vs 36 months equal HR 1.2 (although 78% vs 70% relapse free). @RheumNow #ACR22 Abstr#0527 https://t.co/IWQmcGeRiW
Janet Pope Janetbirdope
3 years 10 months ago
So great to be in person for higher learning in #rheumatology #ACR22 @RheumNow also the onliners are welcomed https://t.co/JIcyV7v1Ws
Richard Conway RichardPAConway
3 years 10 months ago
Khanna @sclerodermaUM. SLS-III MMF+Pirfenidone vs MMF alone in SSc-ILD. Underpowered due to COVID (51 vs 150). No difference FVC 18 months ?more rapid improvement in combo. Better HRCT, PROs in combination. Need another study! @RheumNow #ACR22 Abstr#0520 https://t.co/K2Ne6PSHkS https://t.co/P6A7OJpzCf
Akhil Sood MD AkhilSoodMD
3 years 10 months ago
#Abstr 0542 ASAS EULAR Recommendations for Management of axSpA
'Absence of response to treatment should prompt re-evaluation of the diagnosis and consideration of the presence of comorbidities.'
@RheumNow #ACR22
